The FDA has listed an ongoing Class II recall of a premixed Nexterone (amiodarone) 360 mg/200 mL single-dose GALAXY container by Baxter Healthcare, for current good manufacturing practice (CGMP) deviations.
A Class II recall means use may cause temporary or medically reversible harm, with a remote probability of serious harm; here it reflects a manufacturing-quality deviation rather than a safety problem with amiodarone itself. The practical action is logistical: check stock against the recalled lots, quarantine affected units, and ensure an alternative amiodarone preparation is available for arrhythmia and arrest use.
- An ongoing Class II recall affects a premixed Nexterone (amiodarone) 360 mg/200 mL product.
- The reason is manufacturing (CGMP) deviations, not a safety signal about amiodarone.
- Check department and pharmacy stock against the recalled lots and quarantine affected units.
- Ensure an alternative amiodarone preparation is on hand for arrhythmia and arrest care.
Why it matters
Amiodarone is a front-line arrhythmia and arrest drug, so a supply recall is an operational risk even when the drug itself is unaffected.
Don't overread it
A Class II CGMP recall is a manufacturing-quality action for specific lots, not evidence of harm from amiodarone as a medicine.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for emergency & critical care, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free